Speech disorder

Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD

Retrieved on: 
Thursday, January 26, 2023
Mental health, Ketamine, Peripheral nervous system, Vomiting, Suicide, PTSD, Post-traumatic stress disorder, Nausea, Tissue (biology), Speech disorder, Risk, OTC, United States Patent and Trademark Office, Hallucination, Depression, Neck, Patient, Patent, Anxiety, Lethargy, Hope, Neuro, Toxicity, Pain, Pharmaceutical industry

MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic stress disorder (PTSD).

Key Points: 
  • MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic stress disorder (PTSD).
  • The provisional patent application describes ketamine formulations for topical administration and related methods of treating PTSD, utilizing NeuroDirect™ non-systemic drug delivery technology.
  • These novel ketamine formulations, and methods of treatment, are being developed to reduce the side effects caused by prior formulations, such as hallucinations, nausea, lethargy, and toxicity, but more importantly to also reduce pain and symptoms of PTSD.
  • “PTSD can be a serious mental health disorder, with no known effective therapeutic solutions currently available.

Addex Provides Corporate Update and Financial Guidance

Retrieved on: 
Thursday, January 19, 2023
IND, Glutamate (neurotransmitter), Partner, Janssen, Psychosis, GABA, Depression, SUD, CHF, ADX71149, Speech disorder, Partnership, NAM, Glutamic acid, PTSD, Patient, Chronic cough, Research, Epilepsy, Stroke, LR, Schizophrenia, Pain, Pharmaceutical industry, Indivior

53 LR

Key Points: 
  • 53 LR
    Geneva, Switzerland, January 19, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today provided a corporate update, including a review of its pipeline and financial guidance.
  • “We ended 2022 with CHF7.0 million of cash and expect to be able to finance our operations until Q3 2023.
  • We continue to focus on entering into collaborative arrangements across our pipeline to secure the financial resources to advance their development and strengthen our balance sheet,” said Tim Dyer, CEO of Addex.
  • The program is currently in clinical candidate selection phase, with IND enabling studies expected to be initiated in late 2023.

Psilocybin Behavioral Health Access and Services Act Endorsed by United Food and Commercial Workers Local 360

Retrieved on: 
Thursday, January 19, 2023
Mental Health, Professional Services, Public Policy, Government, Other Natural Resources, Agriculture, Natural Resources, Alternative Medicine, Hemp, Health, Specialty, Cannabis, State, Local, Retail, Other Policy Issues, Legal, Labor, United Food and Commercial Workers, Trade, Psilocybin, Depression, Anxiety, UFCW, Senate, Speech disorder, Partnership, Legislation, Food, Charles D. Hudson Transitional Center, New Jersey General Assembly, Research, Pain

United Food and Commercial Workers (UFCW) Local 360 is proud to publicly endorse New Jersey Assembly Bill A4911, authorizing production and use of psilocybin to promote health and wellness.

Key Points: 
  • United Food and Commercial Workers (UFCW) Local 360 is proud to publicly endorse New Jersey Assembly Bill A4911, authorizing production and use of psilocybin to promote health and wellness.
  • Importantly, A4911 both decriminalizes psilocybin production, possession, use, and distribution, and expunges past offenses.
  • “We welcome the introduction of this thoughtful piece of legislation,” said Sam Ferraino, president of UFCW Local 360.
  • Local 360 looks forward to working with legislators and industry to replicate that success when psilocybin is legalized.

Sprouts Farmers Market Features Cupcake Collaboration between Washington Red Raspberry Growers and Social-Mission Company Rubicon Bakers

Retrieved on: 
Monday, January 9, 2023
Sprouts, Taste, Partnership, Sprouts Farmers Market, Research, Rubicon, Running, Employment, Farmers' market, Imprisonment, Farmer, Development, Certification, Housing, Speech disorder, Soft drink, Food industry, Sprout

LYNDEN, Wash., Jan. 9, 2023 /PRNewswire/ -- Consumers nationwide can now purchase Rubicon Bakers' Vegan Lemon Raspberry Cupcakes at over 380 Sprouts Farmers Market stores nationwide. Sprouts is the latest retailer to feature this creative collaboration between Washington red raspberry farmers and the Certified B Corporation, Rubicon Bakers. The cupcakes will be available for a limited time as part of Sprouts' seasonal citrus event beginning December 26 and running until March 5.

Key Points: 
  • Sprouts is the latest retailer to feature this creative collaboration between Washington red raspberry farmers and the Certified B Corporation, Rubicon Bakers.
  • The Washington red raspberry industry partnered with Rubicon Bakers' Research and Development team to feature a Washington red raspberry puree in both the filling and icing – the perfect complement to Rubicon's light and citrusy vegan lemon cupcake.
  • Rubicon Bakers' Vegan Lemon Raspberry Cupcakes use Washington red raspberry puree to create a delicious icing featuring a rich pink hue and sweet-tart raspberry flavor achieved using only raspberries.
  • In honor of the latest retail partnership, Rubicon Bakers and the Washington Red Raspberry Commission will run a promotion in Sprouts Farmers Market stores during the first two weeks of February.

Shatterproof Applauds the Passage of the MATE Act to Expand Addiction Education

Retrieved on: 
Friday, December 23, 2022
Public Policy, Government, White House, Federal Government, Public Policy, General Health, Health, Mental Health, Healthcare Reform, Congressional News, Views, Well, Education, Doctor of Nursing Practice, Addiction, Mental health, Legislation, School, Pain, SUD, Substance-related disorder, American College, Health, Voices, Omnibus Appropriations Act, 2009, SMART Recovery, House, Drug Safety, Organization, Buprenorphine, National Council, Drug Enforcement Administration, Federation, National Safety Council, American Society of Addiction Medicine, Drug, Opioid use disorder, Research, MAT, Patient, Representative, Curriculum, Society, Oxford, OUD, Maintenance, Student, American College of Medical Toxicology, MATE, Congress, Suds, Louisiana House of Representatives, University, Addiction medicine, DEA, Speech disorder, Pharmaceutical industry, Medicine, The 39 Clues

Shatterproof applauds the passage of the Medication Access and Training Expansion (MATE) Act (H.R.

Key Points: 
  • Shatterproof applauds the passage of the Medication Access and Training Expansion (MATE) Act (H.R.
  • Passage of the MAT Act along with the MATE Act will enable better access to life-saving treatment.
  • The MATE Act mainstreams addiction medical education on SUDs across the nation’s medical educational programs.
  • Shatterproof worked closely with the American Society of Addiction Medicine on the passing of the MATE Act.

CaseWorthy, Inc. Acquires Leading Health and Humans Services Software Company MediSked

Retrieved on: 
Friday, January 6, 2023
Government, Education, UT, Data collection, Brain, Symphony Technology Group, Social, Case management, Assistant Secretary of Health and Human Services for Planning and Evaluation, STG, News, Employment, Acquisition, Coordinate system, Disability in Canada, Health, Connect, Ageing, Speech disorder, Health insurance, Management

ROCHESTER, N.Y., Jan. 6, 2023 /PRNewswire/ -- Salt Lake City, UT based CaseWorthy, Inc, backed by private equity firm Symphony Technology Group ("STG"), has made a majority investment in MediSked, LLC., a leading health and human services software provider that enables publicly funded agencies and non-profits as well as care management administrative entities to manage care to individuals receiving home and community based services, such as those with intellectual and developmental disabilities, substance use disorders or brain injuries, with its Connect and Coordinate software solutions. This acquisition represents a substantial investment in the innovative convergence of social services and health and human services to deliver a whole-person care solution, a market first.

Key Points: 
  • This acquisition represents a substantial investment in the innovative convergence of social services and health and human services to deliver a whole-person care solution, a market first.
  • "We are excited to combine CaseWorthy's mission-critical social services capabilities with MediSked's market-leading health and human services offerings.
  • This is great news for our customers and for the human services experience within our communities," said Doug Golub, President and Co-Founder of MediSked.
  • CaseWorthy has more than 300 clients in the Social and Human Service industry spanning verticals that include employment, homeless management, senior and aging services, education, victims services, health and human service agencies, and children and family services.

Arizona Experiencing Increase in Illicit Fentanyl Exposure

Retrieved on: 
Thursday, December 8, 2022
Mental Health, Public Policy, Government, Health, State, Local, Other Health, Pharmaceutical, Doctor of Pharmacy, JAMA Network Open, Speech disorder, Medical statistics, National Center for Health Research, Drug overdose, Fentanyl, Public health, Chronic pain, UDT, Illegal drug trade, Veni, vidi, vici, DEA, Death, Multimedia, Education, CPE, Drug Enforcement Administration, Urine, CDC, National Center for Health Statistics, Pharmaceutical industry, Medical device, Drug

Millennium Health announced today that illicit fentanyl positivity in Arizona increased by 261% in patient samples from substance use disorder treatment practices tested during the first half of 2022 compared to 2019.

Key Points: 
  • Millennium Health announced today that illicit fentanyl positivity in Arizona increased by 261% in patient samples from substance use disorder treatment practices tested during the first half of 2022 compared to 2019.
  • View the full release here: https://www.businesswire.com/news/home/20221208005157/en/
    Arizona saw a 260% increase in fentanyl positivity in the first half of 2022 compared to all of 2019 based on real-time analysis of urine drug test results by Millennium Health.
  • (Graphic: Business Wire)
    A dramatic increase in drug overdose deaths is being reported across the U.S.
  • We also conduct real-time tracking of emerging drug use trends to help researchers, public health officials, and policymakers address the significant increase in drug overdose deaths.

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook

Retrieved on: 
Wednesday, December 7, 2022
Speech disorder, Substance-related disorder, Person, NR, Conditional sentence, Environment, Risk, OHS, OUD, Patient, Communication, Science, BMAT, Annual report, Research, SUD, Buprenorphine, LON, EST, Risperidone, Government, EGM, COVID-19, Growth, Trial of the century, Multimedia, Capital market, RSVP, SG, Acquisition, Management, Bank, Security (finance), Health insurance, Marketing, Risk management, Indivior, Shareholder

SLOUGH, England and RICHMOND, Va., Dec. 7, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) willhold a Capital Markets Day today in New York City.

Key Points: 
  • SLOUGH, England and RICHMOND, Va., Dec. 7, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) willhold a Capital Markets Day today in New York City.
  • The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company's strategic growth plans and roadmap for delivering long-term shareholder value.
  • Within this outlook, which is based on its current business portfolio, Indivior also expects a return to NR growth in the Rest of the World driven by new products SUBLOCADE (SUBUTEXPR) and SUBOXONE(buprenorphine/naloxone) Film.
  • Indivior expects to achieve significant operating margin expansion over the medium-term driven by an improving gross margin and focused management of operating expenses.

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook

Retrieved on: 
Wednesday, December 7, 2022
Speech disorder, Substance-related disorder, Person, NR, Conditional sentence, Environment, Risk, OHS, OUD, Patient, Communication, Science, BMAT, Annual report, Research, SUD, Buprenorphine, LON, EST, Risperidone, Government, EGM, COVID-19, Growth, Trial of the century, Capital market, RSVP, SG, Acquisition, Management, Bank, Security (finance), Health insurance, Risk management, Indivior, Shareholder

SLOUGH, England and RICHMOND, Va., Dec. 7, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) willhold a Capital Markets Day today in New York City.

Key Points: 
  • SLOUGH, England and RICHMOND, Va., Dec. 7, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) willhold a Capital Markets Day today in New York City.
  • The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company's strategic growth plans and roadmap for delivering long-term shareholder value.
  • Within this outlook, which is based on its current business portfolio, Indivior also expects a return to NR growth in the Rest of the World driven by new products SUBLOCADE (SUBUTEXPR) and SUBOXONE(buprenorphine/naloxone) Film.
  • Indivior expects to achieve significant operating margin expansion over the medium-term driven by an improving gross margin and focused management of operating expenses.

Growth in Artificial Intelligence Offers Opportunity for Health-System Pharmacy

Retrieved on: 
Monday, December 5, 2022
Pharmacy, Maintenance, Speech disorder, Exercise, Abramowicz, Trial balance, Patient, Health, Pharmacy technician, Future Fund, AI, Strategic planning, COVID-19, Pharmacist, Artificial intelligence, Computer security, Health information management, Workforce, Pharming, LAS, Numbering Resource Utilization/Forecast Report, ASHP, Student, Pressure, Algorithm, Organization, Hospital, Medical device, Management, Medicine

LAS VEGAS, Dec. 5, 2022 /PRNewswire/ -- The use of artificial intelligence (AI) will expand in coming years throughout health systems and their pharmacy enterprises, providing numerous opportunities to improve care and care delivery with algorithms supporting many routine tasks and freeing pharmacists to focus on more complex challenges like pharmacogenomic-guided medication use, hospital-at-home, and telehealth, according to the 2023 ASHP/ASHP Foundation Pharmacy Forecast Report that was released at the ASHP Midyear Clinical Meeting & Exhibition.

Key Points: 
  • "The 2023 Pharmacy Forecast Report recommendations provide clear guidance for pharmacy leaders as they respond to the rapidly evolving healthcare environment," said ASHP CEO Paul W. Abramowitz, Pharm.D., Sc.D.
  • The Pharmacy Forecast advises that key pharmacy staff be trained in AI and recommends that pharmacy leaders help health systems establish priorities, best practices, and long-term maintenance of medication-related AI tools.
  • The COVID-19 pandemic's impact on all levels of the pharmacy workforce and the supply chain is also addressed in the 2023 Pharmacy Forecast.
  • The Pharmacy Forecast published online ahead of print and will appear in print in the Jan. 15, 2023, issue of AJHP.